|
|
Article: Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG.
- Article from:
- Business Wire
- Article date:
- September 13, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* Company gains access to proprietary antibody fragment technology particularly suited to treat eye diseases
* Acquisition establishes sustainable platform for ongoing biologics development
* Deal builds on other recent transactions to expand breadth and depth of Alcon's development opportunities in eye care in the long term
* ESBATech shareholders retain rights to non-ophthalmic technology and products
HUENENBERG, Switzerland & ZURICH -- Alcon (NYSE:ACL) announced today that it has entered into a definitive agreement to acquire ESBATech AG, a Swiss biotechnology company. Alcon will pay ESBATech shareholders $150 million in cash at ...